Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.7
3.0
Journals
Diagnostics
Special Issues
Advances in Diagnosis and Treatment of Bone and Soft Tissue...
share announcement

Advances in Diagnosis and Treatment of Bone and Soft Tissue Sarcoma

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".

Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 4652

Special Issue Editor

Dr. Tomoki Nakamura

E-Mail Website
Guest Editor
Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu 514-8570, Japan
Interests: orthopedic oncology; soft tissue sarcoma; bone sarcoma; metastasis; limb salvage surgery

Special Issue Information

Dear Colleagues,

Recently, the prognosis has been improved for diagnosing and treating bone and soft tissue sarcoma in the extremities due to advances in surgical techniques, chemotherapy, and imaging modalities. Survival in patients with bone and soft tissue sarcoma improved in the 1990s and 2000s. However, orthopedic oncologists have still faced infiltrative aggressive tumors, unresectable tumors, and advanced metastatic tumors. The prognosis has not changed over the last 20 years. To overcome those, new diagnoses and treatments should be developed.

Therefore, in this Special Issue, I would like to invite original papers and review articles that describe possible new techniques of diagnostic devices, surgery, and radiotherapy. Possible chemotherapy and immunotherapy for improving survival in patients with bone and soft tissue sarcoma are also welcome.

Both basic and clinical research are invited.

I am looking forward to receiving your contribution.

Dr. Tomoki Nakamura
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • bone sarcoma
  • soft tissue sarcoma
  • diagnosis
  • treatment
  • surgery
  • radiotherapy
  • chemotherapy
  • immunotherapy

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

12 pages, 1140 KiB  
Article
Diagnostic Superiority of Dual-Time Point [18F]FDG PET/CT to Differentiate Malignant from Benign Soft Tissue Tumors
by Philippe d’Abadie, Olivier Gheysens, Renaud Lhommel, François Jamar, Thomas Kirchgesner, Filomena Mazzeo, Laurent Coubeau, Halil Yildiz, An-Katrien De Roo and Thomas Schubert
Diagnostics 2023, 13(20), 3202; https://doi.org/10.3390/diagnostics13203202 - 13 Oct 2023
Cited by 1 | Viewed by 1049
Abstract
[18F]FDG PET/CT is used in the workup of indeterminate soft tissue tumors (STTs) but lacks accuracy in the detection of malignant STTs. The aim of this study is to evaluate whether dual-time point [18F]FDG PET/CT imaging (DTPI) can be [...] Read more.
[18F]FDG PET/CT is used in the workup of indeterminate soft tissue tumors (STTs) but lacks accuracy in the detection of malignant STTs. The aim of this study is to evaluate whether dual-time point [18F]FDG PET/CT imaging (DTPI) can be useful in this indication. In this prospective study, [18F]FDG PET/CT imaging was performed 1 h (t1) and 3 h (t2) after injection. Tumor uptake (SUVmax) was calculated at each time point to define a retention index (RI) corresponding to the variation between t1 and t2 (%). Sixty-eight patients were included, representing 20 benign and 48 malignant tumors (including 40 sarcomas). The RI was significantly higher in malignant STTs than in benign STTs (median: +21.8% vs. −2%, p < 0.001). An RI of >14.3% predicted STT malignancy with a specificity (Sp) of 90% and a sensitivity (Se) of 69%. An SUVmaxt1 of >4.5 was less accurate with an Sp of 80% and an Se of 60%. In a subgroup of tumors with at least mild [18F]FDG uptake (SUVmax ≥ 3; n = 46), the RI significantly outperformed the diagnostic accuracy of SUVmax (AUC: 0.88 vs. 0.68, p = 0.01). DTPI identifies malignant STT tumors with high specificity and outperforms the diagnostic accuracy of standard PET/CT. Full article
(This article belongs to the Special Issue Advances in Diagnosis and Treatment of Bone and Soft Tissue Sarcoma)
►▼ Show Figures

Figure 1

Review

Jump to: Research

16 pages, 1824 KiB  
Review
Biology and Management of High-Grade Myxofibrosarcoma: State of the Art and Future Perspectives
by Jun Nishio and Shizuhide Nakayama
Diagnostics 2023, 13(19), 3022; https://doi.org/10.3390/diagnostics13193022 - 22 Sep 2023
Cited by 2 | Viewed by 3020
Abstract
Myxofibrosarcoma (MFS) is one of the most common adult soft tissue sarcomas, typically arising in the extremities. Histologically, MFS is classified into three grades: low, intermediate, and high. Histological grades correlate with distant metastases and tumor-associated mortality. The diagnosis of MFS is challenging [...] Read more.
Myxofibrosarcoma (MFS) is one of the most common adult soft tissue sarcomas, typically arising in the extremities. Histologically, MFS is classified into three grades: low, intermediate, and high. Histological grades correlate with distant metastases and tumor-associated mortality. The diagnosis of MFS is challenging due to a lack of well-characterized immunohistochemical markers. High-grade MFS displays highly complex karyotypes with multiple copy number alterations. Recent integrated genomic studies have shown the predominance of somatic copy number aberrations. However, the molecular pathogenesis of high-grade MFS remains poorly understood. The standard treatment for localized MFS is surgical resection. The systemic treatment options for advanced disease are limited. This review provides an updated overview of the clinical and imaging features, pathogenesis, histopathology, and treatment of high-grade MFS. Full article
(This article belongs to the Special Issue Advances in Diagnosis and Treatment of Bone and Soft Tissue Sarcoma)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop